MetaCap

Neurocrine Biosciences Inc. (NBIX)

NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

150.57-6.02 (-3.84%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NBIX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$15.24B
52-week range
122.14 – 186.12
Day range
150.24 – 158.26
Volume / Avg
1.59M / 1.34M
Beta
—

52-week range

$122.14$186.12

NBIX stock today

On Nov 20, NBIX ended the session at $150.57, shedding $6.02 (3.84%), versus the S&P 500's 3.70% decline. Shares are 19.1% below their 52-week high of $186.12, set on Jul 30, 2026 and 23.3% above the 52-week low of $122.14, in the middle of the past year's range. NBIX is up 6.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.2%.

At 22.3x trailing earnings, Neurocrine Biosciences trades below the peer-group median of 26.6x. Its forward P/E of 12.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Neurocrine Biosciences

Company profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Kyle W. Gano Ph.D.
Headquarters
San Diego, CA
Employees
2,500
IPO year
1996

Financial highlights

Full financials

In fiscal 2025, Neurocrine Biosciences generated $2.86 billion in revenue, up 21.4% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $478.6 million (+40.2% year over year), for a net margin of 16.7% versus a median of 13.2% in the prior 5 years. Gross margin was 98.2% (down from 98.6%) and operating margin 21.6%.

Neurocrine Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B
Growth+21.45%+24.81%+26.76%+31.34%+8.38%
Net income$478.60M$341.30M$249.70M$154.50M$89.60M
EPS (diluted)$4.67$3.29$2.47$1.56$0.92

Analyst forecast

Forecast

Consensus (28 analysts)

strong_buy

Avg. price target

$208.54+38.50%

  • Strong buy 4
  • Buy 20
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $150.00High $253.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$2.04 vs $1.95
Surprise
+4.62%

NBIX news

All NBIX news

Neurocrine Biosciences peers

Health Care sector
NBIX peer companies
CompanyPrice% ChgMarket capCompare
EXELExelixis Inc.64.63-1.82%$15.77Bvs NBIX
TECHBio-Techne Corp72.67-0.04%$11.42Bvs NBIX
RGENRepligen Corporation163.81-3.81%$10.47Bvs NBIX
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs NBIX
BNTXBioNTech SE ADR80.96-0.52%$20.07Bvs NBIX
QGENQiagen N.V.49.30-0.66%$10.18Bvs NBIX
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs NBIX
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs NBIX

Indexes, lists and sector

Neurocrine Biosciences stock FAQ

What is Neurocrine Biosciences's stock price today?

NBIX last traded at $150.57 as of Nov 20, 4:00 PM EST, down 3.84% on the day. Prices are delayed at least 15 minutes.

What is NBIX's P/E ratio?

NBIX trades at a trailing P/E ratio of 22.34 and a forward P/E of 12.24, compared with a median of 26.6 for its closest peers.

Who is Neurocrine Biosciences's CEO?

Mr. Kyle W. Gano Ph.D. is the chief executive officer of Neurocrine Biosciences Inc., which has about 2,500 employees.

What is the NBIX 52-week high?

The 52-week high for NBIX is $186.12 and the 52-week low is $122.14. The stock is currently 19.1% below its high.

Compare NBIX